Efficacy and Safety of Lumiracoxib
Phase 3
Completed
- Conditions
- Osteoarthritis
- Registration Number
- NCT00267215
- Lead Sponsor
- Novartis
- Brief Summary
This trial assessed the safety and efficacy of a single dose of lumiracoxib 400 mg compared to placebo and to a single dose of celecoxib 200mg. It also assessed safety and efficacy of 400mg lumiracoxib administered once a day for 7 days compared to placebo and to 200 mg celecoxib twice daily.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 330
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Assess the short-term (3-5 hours) analgesic efficacy of COX189, 400mg administered once a day for 7 days, compared to placebo and to 200mg celecoxib bid
- Secondary Outcome Measures
Name Time Method Assess the safety and tolerability profile of COX189 in comparison to placebo and celecoxib
Trial Locations
- Locations (1)
Novartis
🇩🇪Nuernberg, Germany